Sarepta Therapeutics, Inc. (SRPT)
NEUTRALFundamental
44
Preço
$18.80
Capitalização de Mercado
$1.92B
Parte 1 · Quanto vale a empresa
Visão Geral
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$1.47B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-137M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$-307M
Capital Próprio Total
$1.14B
Passivo Total
$2.21B
Rácio de Liquidez
4.42
Cobertura de Juros
18.35
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$14.99
Preço Atual
$18.80
Margem de Segurança
-25.5%
Intervalo de Valor Justo
$9.75 - $20.24
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-62.5%
Rácio P/B
1.25
P/FCF
23.40
Margem Bruta
98.6%
ROIC
-24.5%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-24.5%
WACC
6.2%
ROIC − WACC
-30.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (10)
- Gross Margin 98.6%
- P/FCF 23.40
- P/B Ratio 1.25
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 32.4%
- Share Dilution -0.5%
Reprovado (12)
- EPS shows upward trend
- Price CAGR -3.71%
- ROIC -24.5%
- Operating Margin -37.5%
- CapEx intensity
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -10.0%
- Analyst Consensus 42% Buy
- Earnings Surprise avg -12.2%
- Net Margin Trend -9.3% vs -2.6%
- Piotroski F-Score 3/9
Indisponível (5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Ian Michael Estepan | President & COO | 49 |
| Mr. Ryan H. Wong | Executive VP & CFO | 46 |
| Ms. Cristin L. Rothfuss J.D. | Executive VP, General Counsel & Company Secretary | 57 |
| Mr. Douglas S. Ingram Esq., J.D. | Advisor | 62 |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations | 47 |
| Dr. Michael E. Severino M.D. | CEO & Director | 59 |
| Rachael Potter Ph.D. | Chief Scientific Officer | - |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations | - |
| Ms. Alison Nasisi | Executive VP & Chief People Officer | - |
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer | - |
Risco de Auditoria
7
Risco do Conselho
2
Risco de Remuneração
10
Risco dos Direitos dos Acionistas
3
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for SRPT, sourced from Markets Gazette.
- 3/19/2026NEGATIVESarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta Therapeutics Inc. (SRPT) shares experienced a decline following an update from the U.S. Food and Drug Administration (FDA) and mixed clinical trial results for its Duchenne muscular dystrophy drugs. While the company intends to seek traditional approvals, the market is currently weighing the potential for regulatory success against the less-than-convincing trial data. This uncertainty introduces significant risk for investors, as the path to full approval appears more challenging than initially anticipated, potentially impacting future revenue streams and market valuation.
- 2/25/2026NEUTRALSarepta (SRPT) Q4 2025 Earnings Call Transcript
The market awaits crucial details regarding Sarepta Therapeutics' (SRPT) Q4 2025 earnings call transcript. While the event was scheduled, specific information on financial results, future projections, and updates on key products has not yet been made public. Investors will closely monitor the release of this data to assess the company's performance during the period and its growth prospects, particularly concerning advancements in neuromuscular disease treatments. The immediate lack of details maintains a climate of uncertainty, with the stock potentially reacting significantly once the information becomes available and is analyzed by market participants.
via Markets Gazette